A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

Roche Pharma AG

Information provided by (Responsible Party):

Genentech, Inc.

ClinicalTrials.gov Identifier:

NCT00676715

First received: May 9, 2008

Last updated: September 1, 2016

Last verified: September 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Primary Completion Date:	September 2009 (Final data collection date for primary outcome measure)
Certification or Request for Extension to Delay Results Received:	March 25, 2013